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Background: During chronic kidney disease progression, kidney-specific risk factors for cardiovascular disease come
into play. The present study investigated the impact of indoxyl sulfate, dietary tryptophan-derived uremic toxin,
accumulated in the blood of patients with chronic kidney disease on hemostatic parameters, markers of
inflammation, oxidative stress and monocyte to macrophage transition.
Methods: Fifty-one CKD patients not undergoing hemodialysis were enrolled in the study. Coagulation factors,
fibrinolytic parameters, adhesion molecules, endothelial dysfunction markers, oxidative stress as well as
inflammation markers were examined using immune-enzymatic method. Indoxyl sulfate levels were assessed using
high-performance liquid chromatography. Biochemical parameters were determined by routine laboratory
techniques using an automated analyzers. All assessed parameters were compared with controls and subjected to
cross-sectional statistical analysis.
Results: Elevated concentrations of indoxyl sulfate, the vast majority of parameters affecting hemostasis, and
markers of renal insufficiency conditions were observed. Part of hemostatic factors, namely tissue factor, von
Willebrand factor, thrombomodulin, soluble urokinase-type plasminogen activator receptor, soluble intercellular
adhesion molecule-1, soluble vascular cell adhesion protein were correlated with the fraction of indoxyl sulfate. A
significant quantity of assessed parameters showed strong correlations with superoxide-dismutase, renal insufficiency
rate, C-reactive protein, and neopterin. Levels of indoxyl sulfate were independently associated with markers of
impaired endothelial function (thrombomodulin, adhesion molecules), oxidative stress (superoxide-dismutase) and
monocytes activation determinant (neopterin), which indicate unconventional links between these systems and the
role of indoxyl sulfate. Furthermore, parameters that correlated with the levels of indoxyl sulfate (von Willebrand factor,
soluble urokinase-type plasminogen activator receptor, soluble intercellular adhesion molecule-1) were positively
associated with the prevalence of cardiovascular disease in a CKD patients.
Conclusions: The study demonstrated that in conditions of chronic exposure to uremic toxins, indoxyl sulfate seems
to be one of the “missing links” between impaired renal function and prevalence of cardiovascular events, especially
hemostatic disorders. The main functions of the action appear to be altered monocytes activation, intensified
inflammatory process, and augmented oxidative stress by this uremic toxin.
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Chronic kidney disease (CKD) is an established risk
factor for the occurrence of hemostatic disorders and
the increased prevalence of cardiovascular disease
(CVD) [1, 2]. Traditional cardiovascular risk factors
are insufficient to explain the high coincidence of
CVD among CKD patients, suggesting the existence
of “missing links” connecting cardiovascular system
and kidney [3].
Clinical observations provide evidence of the coexist-
ence of two opposite thrombotic and bleeding tenden-
cies that are commonly observed in CKD patients.
Disturbances in hemostasis during CKD are manifested
in episodes of spontaneously induced prothrombotic
states or severe bleeding symptoms and represent an im-
portant cause of the morbidity and mortality in patients
with impaired renal function [1, 4]. The causes of
hemostasis abnormalities in CKD are extremely compli-
cated, depend on many factors and are still not fully
understood despite many years of research.
Hypercoagulability is caused by abnormal activity of
coagulation regulatory factors and the platelet hyper-
reactivity, while excessive bleeding is the result of inad-
equate function of platelets, the coagulation cascade fac-
tors and/or intensified activity of the fibrinolysis [5]. The
endothelial cells (ECs), cellular adhesion molecules
(CAMs), the vessel wall and its extracellular matrix play
some roles in the etiology of hemostatic disturbances
[6]. Furthermore, patients with impaired renal function
are at enhanced risk of inflammation, oxidative stress
(SOX), fluid retention, further impairment of endothelial
function, and anemia – conditions specific to renal dis-
ease [7, 8]. Above-mentioned components are firmly in-
fluenced by uremic toxins and metabolic compounds
accumulated in CKD patients serum due to its inad-
equate renal clearance [9]. Altogether, it results in a
mutual intensification of hemostatic disorders and pro-
gression of CKD.
Indoxyl sulfate (IS) is an aggressive uremic toxin
that is markedly accumulated in the plasma of pa-
tients with CKD and its concentration in CKD pa-
tients can increase even 50-fold compared to healthy
people [10]. IS is the end-stage product of dietary
tryptophan metabolism and due to its high-affinity
binding to albumins cannot be efficiently removed by
hemodialysis. It exerts prooxidative and proinflamma-
tory activity, triggers of the immune response, and
stimulates the progression of CKD [11]. The com-
pound exhibits its cellular toxicity in renal tubular
cells, glomerular mesangial cells, and vascular smooth
muscle cells (VSMCs) via numerously signaling path-
ways alterations [12]. Besides, IS inhibits ECs prolifer-
ation and viability, stimulates endothelium for secretion of
chemokines and CAMs, and enhance expression ofhemostasis-related molecules on their surface [13].
Recently, uremic toxins have been suggested as a po-
tential “missing link” between CKD and the presence
of CVD [3]. Many authors indicate a potential role of
IS in the progression of vascular and hemostatic dys-
functions through the induction of SOX and progres-
sive inflammatory process. According to Shivanna
et al. [14] and Chitalia et al. [15] IS is a potential
CKD-related prothrombotic uremic toxin that induces
tissue factor (TF) in VSMCs and increases post-
vascular interventional prothrombotic risk by TF-
dependent manner. Recent study of Tang et al. indi-
cated that IS exerts modulatory activities towards K+
channels leading to the development of arrhythmo-
genesis in CKD patients [16]. Previous studies con-
ducted using in vitro methods and animal models
provided presumptive evidence suggesting that IS may
be considered as a molecule responsible for throm-
botic events in CKD patients [14, 15]. Despite the ex-
istence of background information on the potential IS
impact on hemostasis, currently, there are no studies
discussing in a comprehensive manner this influence,
especially during CKD, when the levels of IS are per-
manently increased. Taking this into consideration,
the aim of our study was to investigate the potential
associations between plasma IS levels and the param-
eters of: coagulation, fibrinolysis and endothelial func-
tion in CKD patients on conservative treatment.
Because SOX, inflammation, and cellular immune ac-
tivation are the recognized factors that may affect the
hemostatic system in this population the markers of
SOX and inflammatory state were also determined [17].
Moreover, we also wanted to determine, if IS-dependent
hemostatic system disturbances were associated with the
prevalence of CVD in this population.
Methods
Patients
Fifty-one predialysis patients with CKD (twenty females,
thirty-one males) on conservative treatment, who were
clinically stable and free of existing infections and auto-
immune diseases, participated in the study. None of the
patients received immunosuppressive therapy, lipid-
lowering drugs, nonsteroidal anti-inflammatory agents,
recombinant human erythropoietin, or antioxidants such
as vitamin E, C, or allopurinol during the study. CKD
was caused by glomerulonephritis (n = 23), diabetic ne-
phropathy (n = 8), adult polycystic kidney disease (n = 7),
pyelonephritis (n = 3), hypertensive nephropathy (n = 2),
and other renal disease (n = 6). Twenty-three patients
(45%) in the past suffered from the CVD defined as the
occurrence of myocardial infarction, ischemic stroke,
coronary revascularization procedures, angina pectoris,
and typical ischemic changes on electrocardiogram.
Table 1 Biochemical and clinical characteristics of control
group and CKD patients
Parameter Controls n = 18 CKD n = 51 P value
Sex M/F 7/11 20/31 NS
Age, years 47.4 ± 6.18 53.3 ± 15.5 NS
BMI, kg/m2 25.83 ± 3.45 24.2 ± 3.55 NS
eGFR, mL/min/1.73 m2 117.0 (105.0 – 125.0) 20.6 (5.6 - 127) 0.0001
Creatinine, mg/dL 0.88 (0.34 – 1.18) 3.32 (0.78 – 9.33) 0.0001
Urea, mg/dL 30.03 ± 6.05 118 ± 53.1 0.0001
hs-CRP, μg/ml 0.42 (0.01 – 9.25) 3.38 (0.01 - 94) 0.0079
Neopterin, nmol/L 5.93 (0.41 – 12.9) 32 (5 – 150) 0.0001
Cu/Zn SOD, ng/ml 51 (6 – 78) 62 (30 – 262) 0.0372
H2O2, μM 55.2 (2.33 – 434) 243 (60.7 – 624) 0.0012
Glucose, mmol/L 92.1 (67–114) 90 (45–186) NS
Total cholesterol, mg/dL 192 (143–248) 199 (106–485) NS
Triglycerides, mg/dL 67 (38–149) 152 (61–620) 0.0001
Total protein, g/dL 6.36 (6.08 – 7.1) 6 (3.2 – 7.8) 0.0261
Albumin, g/dL 4.43 (4.11 – 4.98) 3.3 (0.9 – 8.9) 0.0001
Red blood cells, ×103 μL 4.55 ± 0.31 3.59 ± 0.69 0.0001
White blood cells, ×103 μL 5.77 ± 1.09 6.38 ± 1.98 NS
Lymphocytes, % 33.1 ± 5.38 27 ± 9.85 0.0107
Platelets, ×103 μL 206 (132.0 – 310.0) 184 (76–482) NS
Neutrophils, % 59.19 ± 6.424 59.4 ± 13.1 NS
Hemoglobin, g/dL 14.18 ± 1.3 11.1 ± 2.31 0.0001
Hematocrit, % 42 ± 3.1 33.2 ± 6.15 0.0001
Bilirubin, mg/dL 0.34 ± 0.13 0.48 ± 0.22 0.0157
ALT, U/L 34.5 (16 – 53) 28 (10–130) NS
Smokers, % 20.00 22.65 NS
Pharmacotherapy (%)







Data are shown as mean ± SD or median (range) depending on their normal
or skewed distribution
Abbreviations: Sex M male, Sex F female, BMI body mass index, eGFR estimated
glomerular filtration rate, hs-CRP high sensitivity C-reactive protein, Cu/Zn SOD
superoxide dismutase 1, H2O2 hydrogen peroxide, ALT alanine transaminase,
ACE-inhibitors angiotensin-converting-enzyme inhibitor, ARBs angiotensin
receptor blockers, CKD chronic kidney disease, NS non-significant
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lows: calcium channel blockers (n = 27), ACE inhibitors
(n = 25), β-receptor blockers (n = 23), α-receptor blockers
(n = 4), nitrates (n = 3), and angiotensin-II receptor
blockers (ARBs) (n = 2). Nine patients (17,6%) were
smokers. Drugs affecting hemostasis were not adminis-
tered two weeks prior the study.
Eighteen healthy volunteers matched for age and gen-
der served as a control group. They were not taking any
medications, dietary supplementation, and were on a
standard diet. In the past, hypertension, CKD, diabetes
mellitus, and vascular diseases was not reported. The
volunteers were not taking any drugs affecting hemostasis
two weeks prior the study. Table 1 shows basal character-
istics of CKD patients and control group.
The study protocol was approved by the ethical guide-
lines of Local Ethical Committee in Bialystok and writ-
ten consent was obtained from each subject.
The study was carried out in accordance with the
Declaration of Helsinki.
Blood sampling
Blood was collected from CKD patients and control
group from an antecubital vein in the morning between
8 am and 9 am. Sodium citrate (3,8% in proportion 1 +
9 v/v) was used as an anticoagulant. Citrated plasma and
serum samples were prepared conventionally, aliquoted,
and stored at −80 °C until assayed.
IS determination
IS was determined by liquid chromatography with fluor-
escence detection according to Al Za'abi et al. [18]. The
chromatographic equipment was an Agilent 1200 series
LC-system (Agilent Technologies, Germany) composed
of G1322A degasser, G1311A quaternary pump, G1329A
autosampler and G1330B thermostat for autosampler,
HP1046A fluorescence detector (FLD). Deproteinated
samples were prepared by adding 0.4 ml acetonitrile
containing the methyl paraben (1 mg/ml) as internal
standard into the 0.1 ml plasma. The samples were vor-
texed, kept at 4 °C for 1 min, and then centrifuged for
30 min 14000 g at 4 °C, 1 ml of the supernatant was
injected into HPLC system for analysis. The prepared
samples were separated on column Phenomenex
PEPTIDE 3.6 mm XB-C18 4.6x250mm. The column ef-
fluent was monitored by using programmable FLD. The
optimized conditions were determined by recording
fluorescence spectra with a stop-flow technique. Excita-
tion and emission wavelengths were set at 280/375 nm.
The output of the detector was connected to a single
instrument LC ChemStation. The mobile phase was
composed of acetate buffer (pH 4.5) containing 90%
of acetonitrile and it was pumped at a flow-rate of
0.8 ml/min. Chromatography was carried out at 24 °C.Parameters of hemostatic system
A)Coagulation system
Coagulation system activation was reflected by the
levels of TF and its pathway inhibitor (TFPI) in
the plasma, determined by ELISA kits (IMUBIND
Tissue Factor, IMUBIND Total TFPI Elisa Kit,
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Prothrombin fragments F1+2 (F1+2) were measured
by an ELISA kit (Dade-Behring, Marburg, Germany).
B) Fibrinolytic system
The plasma levels of tissue plasminogen activator
(tPA), urokinase-type plasminogen activator (uPA),
its soluble receptor (suPAR), PAI-1, and plasmin-
antiplasmin complex (PAP) were measured by ELISA
method using commercially kits (IMUBIND tPA
ELISA, IMUBIND PAI-1 ELISA, IMUBIND uPA,
IMUBIND suPAR from American Diagnostica,
Greenwich, CT, USA; Plasmin-α-2-antiplasmin
Complex from Technoclone, Austria).
C) Endothelial function markers
TM and vWF-antigen plasma levels were studied
using commercially available kits (Thrombomodulin
ELISA Kit, American Diagnostica and Asserachrom
vWF, Diagnostica Stago; respectively). Circulating
forms of intercellular adhesion molecule-1 (sICAM-1)
and vascular adhesion molecule-1 (sVCAM-1) were
determined by commercially available ELISA kits
(R&D Systems Europe, Abingdon, UK).
D)Biomarkers of inflammation and oxidative stress
Plasma C-reactive protein levels (hs-CRP) were
measured by high-sensitivity ELISA kits (Imuclone
hs-CRP ELISA, American Diagnostica, Greenwich,
USA). Plasma Cu/Zn superoxide dismutase (Cu/Zn
SOD) levels were measured by ELISA kit (Bender
Med Systems, Vienna, Austria). Total hydrogen
peroxide (H2O2) concentrations were measured with
an Oxy Stat colorimetric assay kit (Biomedica,
Vienna, Austria). Neopterin concentrations were
also determined by ELISA method (Demeditec
Diagnostics, Kiel, Germany).
Biochemical parameters were determined by routine
laboratory techniques using an automated analyzers.
Statistical analysis
The normally distributed data were presented as mean ±
1SD, while the non-Gaussian data as median (full-range).
Normality of distribution was tested using Shapiro-Wilk
W test. The Student t test or nonparametric Mann–
Whitney test were used to compare differences between
CKD group and control group. The χ2 test was used for
categorical variables. The correlations were analyzed
using Spearman’s rank correlation analysis or quasi-
Newton and Rosenbrock’s regression analysis. Multiple
regression analysis was performed using a stepwise
model with a forward elimination procedure to deter-
mine the combined influence of variables on particular
parameters of the hemostatic system. Multiple regres-
sion analysis were performed based on previous results
of Spearman’s rank correlation analysis or quasi-Newtonand Rosenbrock’s regression analysis. A two-tailed p < 0.05
was considered statistically significant. Computations were
performed using GraphPad 6 Prism (GraphPad Software;
La Jolla, California, USA).
Results
Basal characteristics of CKD patients
CKD group did not differ from controls with regard to
gender, age, body mass index, and smoking status.
CKD patients compared to controls showed statistically
significant (p < 0.0001) decreased eGFR values and in-
creased creatinine and urea levels. We also indicated
significantly elevated values of markers of SOX (Cu/Zn
SOD, H2O2), monocyte activation (neopterin) and in-
flammation (hs-CRP) in CKD group compared to con-
trols. The glucose levels and total cholesterol did not
differ between both groups. However, we found in-
creased values of triglycerides (p < 0.0001) and de-
creased levels of total protein and albumins (p = 0.026
and p < 0.0001; respectively). Among morphology pa-
rameters, we did not find any changes in the levels of
white blood cells, platelets, and neutrophils. The CKD
group showed significantly decreased counts of red
blood cells, lymphocytes, hemoglobin, and hematocrit.
Among CKD patients, 45% of them experienced the
presence of CVD. The most frequent used medicines
were ACE-inhibitors, calcium channel blockers, and β-
blockers. The most rarely used drugs were nitrates and
angiotensin receptor blockers. All data are showed in
Table 1.
IS levels and CKD stage
The plasma level of IS was about three-fold higher in
CKD group compared to controls (p < 0.0001). Levels of
IS in controls did not significantly differ from IS concen-
trations in the earliest I + II stages of CKD, whereas the
IS levels were significantly higher in stage III, IV, and V
of CKD compared to controls (p < 0.0001). The signifi-
cantly higher IS concentrations were also observed in
stage III-V compared with stage I + II, (p < 0.0001), as
presented in Fig. 1. IS level correlated with renal dysfunc-
tion markers: eGFR, creatinine (R = −0.685 and r = 0.707,
p < 0.0001; respectively), and with urea concentration
(R = 0.297, p < 0.05).
Parameters of hemostatic system and their associations
with IS concentrations, kidney function markers, SOX and
inflammatory status of CKD patients
As shown in Table 2, TF concentrations in CKD
group were significantly higher compared to controls
(p < 0.0001). The marker of prothrombotic state - F1 + 2
was significantly elevated in patients in comparison to
controls. There were no significant differences between
TFPI levels in CKD and healthies. Furthermore, the
Fig. 1 The levels of IS in control group and CKD group (left) and comparison of the levels of IS among the patients with the different stage of
CKD (right). *** p < 0.001 controls vs CKD group; ^^^ p < 0.001 patients with CKD with III (n = 10) /IV (n = 9) /V (n = 21) stage vs I + II stage (n = 11).
Abbreviations: IS - indoxyl sulfate; CKD - chronic kidney disease; NS - non-significant
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statistical significance (p < 0.0001). All analyzed parame-
ters of the fibrinolysis and the markers of endothelial dys-
function were significantly higher in CKD patients than in
controls.
We noticed the strong positive association between
the concentration of IS and endothelial function
markers: TM, sVCAM-1, sICAM-1 (p < 0.01), whereas
between vWF and IS levels we observed only a weak
correlation (Fig. 2). Among the analyzed parameters
of coagulation and fibrinolysis, only TF and suPAR
levels were significantly and positively associated with
IS concentrations (Fig. 3). Moreover, we found a posi-
tive correlation between plasma levels of IS and the
markers of oxidative stress: Cu/Zn SOD and H2O2, asTable 2 Parameters of coagulation, fibrinolysis and endothelial func
Factor Con
Coagulation TF [pg/ml] 112
F1 + 2 [nmol/ml] 1.04
TFPI [ng/ml] 98.4





Endothelial function vWF [ng/ml] 74.6
TM [ng/ml] 2.8 ±
sICAM-1 [ng/ml] 226
sVCAM-1 [ng/ml] 565
Data are shown as mean ± SD or median (range) depending on their normal or ske
Abbreviations: TF tissue factor, F1 + 2 prothrombin fragments 1 + 2, TFPI tissue factor
activator, suPAR soluble urokinase-type plasminogen activator receptor, tPA tissue p
Willebrand Factor, TM thrombomodulin, sICAM-1 soluble intercellular adhesion mole
disease, NS non-significantwell as between IS and the marker of monocyte
activation - neopterin (Fig. 4). Furthermore, we noticed
the strong positive relationship between Cu/Zn SOD and
neopterin (R = 0.369, p < 0.009), as well as between Cu/Zn
SOD and hs-CRP levels (R = 0.304, p = 0.030). In contrast,
there was no correlation between IS and inflammation
marker - hs-CRP (R = 0185; NS). As presented in
Table 5 (Appendix), the majority of analyzed hemostatic
parameters were inversely associated with kidney
function marker – eGFR and some of them were
positively associated with Cu/Zn SOD and hs-CRP.
What is important, four of analyzed hemostatic pa-
rameters, namely TF, TM, suPAR, and sVCAM-1 were
positively associated with neopterin - marker reflect-
ing monocyte activation status.tion markers in healthy controls and CKD patients
trols CKD P value
(10 – 316) 270 (45 – 1355) <0.0001
(0.66 – 2) 3.42 (0.25 – 14.2) <0.0001
(62.2 – 165) 78.8 (40.4 – 194) NS
(31 – 541) 466 (83.9 – 1735) 0.0085
(0.1 – 1.1) 1.15 (0.6 – 5) <0.0001
(0.07 – 0.2) 2.42 (0.6 – 6.8) <0.0001
(2.8 – 8.9) 7.4 (2 – 70) 0.0096
(13 – 79) 55.7 (12.5 – 96.7) 0.0002
± 9.59 102 ± 13.4 <0.0001
1.11 10.1 ± 4.63 <0.0001
(128 – 286) 263 (143 – 763) 0.0009
(240 – 986) 912 (288 – 3426) 0.0064
wed distribution
pathway inhibitor, PAP plasmin-α2-antiplasmin, uPA urinary plasminogen
lasminogen activator, PAI-1 plasminogen activator inhibitor-1, vWF von
cule-1, sVCAM-1 soluble vascular cell adhesion molecule-1, CKD chronic kidney
Fig. 2 The association between plasma IS levels and the markers of endothelial function in patients with CKD. Results are shown as Spearman’s
rank correlation coefficient (R) and its statistical significance (p values). Abbreviations: IS - indoxyl sulfate; CKD – chronic kidney disease;
TM - thrombomodulin; sVCAM-1 - soluble vascular cell adhesion molecule-1; sICAM-1 - soluble intercellular adhesion molecule-1; vWF -
von Willebrand Factor
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hemostasis, SOX and monocyte activation in patients
with CKD
To examine the combined effect of factors affecting indi-
vidual hemostatic parameters in CKD patients, we per-
formed multiple regression analyses based on results of
Spearman’s rank correlation analysis and quasi-Newton
or Rosenbrock’s regression analysis (Table 3). TM level
was the only factor independently associated with in-
creased TF concentrations (section A). In turn, variables
independently associated with plasma suPAR levels are
presented in section B and variables predicting plasma
endothelial dysfunction markers in patients with CKD







0.289r = 0.0400p =
Fig. 3 The association between plasma IS levels and TF, suPAR concentrati
correlation coefficient (R) and its statistical significance (p values). Abbreviat
suPAR - soluble urokinase-type plasminogen activator receptorindependent variables significantly associated with vWF
concentrations in CKD, whereas PAP, IS and suPAR in-
dependently affected increased TM levels. In the case of
sVCAM-1, the independent variables associated with its
level in CKD group were: IS, sICAM-1, and neopterin.
Moreover, sVCAM-1 and suPAR concentrations inde-
pendently affected sICAM-1 levels in these patients. Be-
cause Cu/Zn SOD and neopterin were proved to be one
of the factors independently affecting some parameters
of the hemostatic system, the additional multiple regres-
sion analyses were performed to demonstrate the inde-
pendent effect of IS on plasma levels of these markers.
As is shown in section D, IS independently affected both











0.521r = p< 0.0001
ons in patients with CKD. Results are shown as Spearman’s rank
ions: IS - indoxyl sulfate; CKD - chronic kidney disease; TF- tissue factor;













0.512r = 0.0001p =












0.632r = < 0.0001p
Fig. 4 The association between plasma IS levels and the markers of oxidative stress and monocyte activation in patients with CKD. Results are
shown as Spearman’s rank correlation coefficient (R) and its statistical significance (p values). Abbreviations: IS - indoxyl sulfate; CKD - chronic
kidney disease; Cu/Zn SOD - Cu/Zn superoxide dismutase 1
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prevalence of CVD in CKD patients
As shown in Table 4, the strong interrelationships
existed between analyzed hemostatic parameters in the
plasma of CKD patients. Furthermore, we observed the
associations between them and the occurrence of CVD.
Among all these factors, levels of sICAM-1 (p < 0.01),
vWF and suPAR (p < 0.05) were positively associated
with the prevalence of CVD in this population. There
was no direct relationship between the presence of CVD
and IS levels (χ2 = 0.072, NS), but the presence of CVD
correlated with Cu/Zn SOD concentrations (χ2 = 4.039,
p = 0.044).
Discussion
The aim of our study was to examine the precise impact
of IS on the hemostatic system in the aspect of the
prevalence of cardiovascular incidents. Existing basis
lead us to consideration that IS may be one of the
“missing links” between CVD and CKD that are closely
interrelated and reinforce each other [19–23]. The re-
sults of our study demonstrated for the first time that:
(1) the increased plasma IS concentrations were associ-
ated with disturbances of hemostatic system, increased
oxidative stress and monocyte activation in patients with
CKD; (2) IS levels, oxidative stress, and monocyte activa-
tion were independently associated with part of the eval-
uated parameters of hemostasis; (3) accumulation of IS
in the plasma of CKD patients may participate in the
risk of CVD prevalence through the mechanism associ-
ated with disturbances of hemostatic system.
Our results are in line with other observations proving
that IS levels are strongly correlated with stages of CKD
[23]. We also found a strong positive association of IS
with Cu/Zn SOD – a recognized marker of oxidative
stress in CKD population [24] as well as a positive rela-
tionship between IS and neopterin, which is synthesized
by monocytes and macrophages in response to interferon-
γ produced by activated T cells [25], what is more, wedemonstrated the strong and independent effect of IS on
these biomarkers, which indicated the direct role of IS in
the generation of SOX and monocyte activation. More-
over, another uremic toxin – p-cresol but not p-cresol sul-
fate (PCS) stimulates monocyte chemoattractant protein-1
(MCP-1) expression via NF-kappa B (NF-κB) p65 in
VSMC [26]. Previously, IS was shown to induce SOX in
cell cultures [27]. Ito et al. [28] used a nephrectomized
mouse model to demonstrate that oral administration of
IS activates numbers of proinflammatory functions and
reactive oxygen species (ROS) production in monocytes.
However, the present study is the first research demon-
strating the direct effect of IS on monocyte activation in
CKD patients.
In accordance with our previous [29, 30] and other
findings [31], we demonstrated the abnormalities of the
hemostatic system in CKD. The maintenance of
hemostasis, which is a complex mechanism, depends on
many factors. Both components of the hemostatic sys-
tem: coagulation and fibrinolysis, are affected by im-
paired endothelial function, inflammation, immune
response, oxidative stress and effects of accumulated
toxins [32]. In the current study, the activation of coagu-
lation cascade was reflected by increased TF level, TF/
TFPI ratio, and an increment of prothrombin fragments
F1 + 2 – an indicator of in vivo thrombin generation
[33]. Simultaneously, the activation of fibrinolysis was
observed in these patients. Among the analyzed parame-
ters of coagulation and fibrinolysis, IS was positively as-
sociated with TF and suPAR values. However, the results
of the multivariate analysis revealed that TM was the
only independent factor affecting increased TF levels in
CKD patients. In contrast, suPAR concentrations were
independently affected by different factors, precisely by
uPA, TM, inflammatory status, monocyte activation and
oxidative stress (Table 3, section B). Interestingly, TF,
suPAR, and TM levels were associated with neopterin
and oxidative status, and the strong relationships existed
between these molecules, as shown in Table 4. Although
Table 3 Variables independently associated with (A) plasma TF,
(B) plasma suPAR, (C) endothelial dysfunctions markers, (D) Cu/Zn
SOD, and neopterin levels in patients with CKD
Independent variable Regression coefficient P value
A TF TM 0.489 0.007
Multiple R for variables in the model– 0.490, multiple R2 – 0.239,
adjusted R2 – 0.211, p < 0.007







Cu/Zn SOD 0.156 0.0482
Multiple R for variables in the model – 0.985, multiple R2 – 0.971,
adjusted R2 – 0.934, p < 0.0001
C vWF age 0.371 0.0104
F1 + 2 −0.276 0.0324
TM* PAP 0.497 0.0003
IS 0.426 0.0008
suPAR 0.399 0.0024
sVCAM-1^ IS 0.562 0.0007
sICAM-1 0.557 0.0008
neopterin 0.359 0.0140
sICAM-1# sVCAM-1 0.547 <0.0001
suPAR 0.357 0.0101
Multiple R for variables in the model – 0.633 (*0.863; ^0.960; #0.785),
multiple R2 – 0.400 (*0.745; ^0.922; #0.617), adjusted R2 – 0.349
(*0.713; ^0.873; #0.574), all p < 0.0001
D Cu/Zn SOD IS 0.411 0.0031
TFPI 0.405 0.0071
sICAM-1 0.366 0.0093
F1 + 2 0.250 0.0442





Multiple R for variables in the model – 0.655 (*0.926), multiple
R2 – 0.429 (*0.857), adjusted R2 – 0.336 (*0.786), both p < 0.0001
Abbreviations: TF tissue factor, TM thrombomodulin, suPAR soluble urokinase-
type plasminogen activator receptor, uPA urinary plasminogen activator,
hs-CRP high sensitivity C-reactive protein, sICAM-1 soluble intercellular adhesion
molecule-1, vWF von Willebrand Factor, Cu/Zn SOD Cu/Zn superoxide dismutase
1, F1 + 2 prothrombin fragments 1 + 2, PAP plasmin-α2-antiplasmin, IS indoxyl
sulfate, sVCAM-1 soluble vascular cell adhesion molecule-1, TFPI tissue factor
pathway inhibitor; CKD – chronic kidney disease
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suPAR and TM [34], the obtained results suggest that
above-mentioned molecules may partially come fromthe activated monocytes [35, 36]. This hypothesis is sup-
ported by observation that plasma levels of vWF, which
is a reliable marker of ECs activation, did not correlate
with TF or TM concentrations (Table 4). Thus, the sig-
nificant elevation of circulating TF and TM, combined
with their strong relationship with the monocyte activa-
tion marker – neopterin, makes activated monocytes
probable (apart from endothelium) source of these mole-
cules in CKD patients. Because in the current study IS
strongly and independently affects the markers of mono-
cyte activation and oxidative stress, we hypothesized that
this uremic toxin can be partially responsible for activa-
tion of ECs and monocytes, which in turn can lead to
the increased release of TF and TM. This hypothesis is
supported by previous observation of Gondouin et al.
[37] showing that IS, through a ROS-mediated mechan-
ism, induces TF expression in monocytes and ECs. In
the case of suPAR, which strongly correlated with vWF,
neopterin and the markers of oxidative stress and in-
flammation, it seems that the different types of activated
cells release this molecule in CKD patients [38].
Endothelial dysfunction is frequently observed in
uremic conditions [32]. The present study confirmed
that the markers of endothelial dysfunction like vWF,
TM, sICAM-1, and sVCAM-1 were markedly elevated in
the plasma of CKD group compared to controls. The
strong positive associations existed between IS, as well
as Cu/Zn SOD and the majority of the endothelial
markers, whereas between IS and vWF only tendency to
positive correlation was observed. Interestingly, all endo-
thelial markers were affected by inflammation (Table 5 -
Appendix). These results indicate that inflammatory
state may be mainly responsible for endothelial dysfunc-
tion in CKD patients, and this is in line with previous
observations [27]. The adhesion of circulating mono-
cytes to endothelium is mediated by cell adhesion mole-
cules, such as ICAM-1 and VCAM-1, which are
upregulated on the ECs surface. Furthermore, ROS
serves as common intracellular messengers for redox-
sensitive pathways, playing a role in the expansion of
vascular disease [39]. ROS can induce endothelial injury
through activation of transcription factor – NF-kB, a key
redox-sensitive regulator of chemokines, cytokines, and
CAMs [40]. Moreover, the mechanism linking ROS with
vascular inflammation has already been documented
[41]. In the condition of the present study, sVCAM-1
was independently affected by plasma IS, neopterin, and
sICAM-1 levels. In addition, we noticed the strong rela-
tionship between this adhesion molecule and the
markers of SOX and inflammation. Although plasma
sICAM-1 was independently associated with sVCAM-1
and suPAR, its levels were also related to oxidative stress
and inflammatory state. What is more, there was a posi-
tive relationship between the markers of oxidative stress
Table 4 The relationships between analyzed hemostatic parameters and cardiovascular disease (CVD) prevalence in patients with
chronic kidney disease (CKD)
vWF TM TF TFPI suPAR uPA tPA sICAM
TF −0.009 0.415 0.165 0.283 0.207 0.048 −0.039
NS 0.002 NS 0.044 NS NS NS
F1 + 2 −0.316 0.077 −0.007 −0.013 0.069 0.101 −0.287 0.068
0.023 NS NS NS NS NS 0.041 NS
TFPI −0.165 0.556 0.165 0.417 0.210 0.067 0.104
NS 0.0001 NS 0.002 NS NS NS
PAP 0.324 0.302 0.063 0.342 0.346 0.176 0.192 0.317
0.020 0.031 NS 0.014 0.013 NS NS 0.023
uPA 0.241 0.493 0.207 0.210 0.605 0.200 0.372
NS 0.0002 NS NS 0.0001 NS 0.007
suPAR 0.479 0.639 0.283 0.417 0.605 0.258 0.525
0.0004 0.0001 0.044 0.002 0.0001 NS 0.0001
tPA 0.307 0.146 0.048 0.067 0.258 0.200 0.055
0.028 NS NS NS NS NS NS
PAI-1 0.319 −0.184 −0.173 −0.009 0.028 0.113 0.363 0.039
0.022 NS NS NS NS NS 0.009 NS
vWF 0.194 −0.008 0.165 0.479 0.242 0.307 0.277
NS NS NS 0.0004 NS 0.028 0.049
TM 0.194 0.415 0.556 0.639 0.493 0.146 0.331
NS 0.002 0.0001 0.0001 0.0002 NS 0.017
sICAM-1 0.277 0.331 −0.039 0.104 0.525 0.372 0.055
0.049 0.017 NS NS 0.0001 0.007 NS
sVCAM-1 0.288 0.598 0.282 0.298 0.656 0.407 0.057 0.654
0.040 0.0001 0.044 0.033 0.0001 0.003 NS <0.0001
CVD 6.400 2.865 1.527 1.191 5.802 0.020 0.554 8.881
0.011 NS NS NS 0.016 NS NS 0.003
Results are shown as Spearman’s rank correlation coefficients (r) or bivariate logistic (χ2) regression coefficient
Abbreviations: TF tissue factor, F1 + 2 prothrombin fragments 1 + 2, TFPI tissue factor pathway inhibitor, PAP plasmin-α2-antiplasmin, uPA urinary plasminogen
activator, suPAR soluble urokinase-type plasminogen activator receptor, tPA tissue plasminogen activator, PAI-1 plasminogen activator inhibitor-1, vWF von
Willebrand Factor, TM thrombomodulin, sICAM-1 soluble intercellular adhesion molecule-1, sVCAM-1 soluble vascular cell adhesion molecule-1, CVD cardiovascular
disease, NS non-significant
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above results, we proposed the hypothesis that IS could
provoke ROS production and CAMs expression, leading
to monocyte-endothelial cell interaction, the initiation of
vascular inflammation and endothelial dysfunction. This
hypothesis is supported by the study of Ito et al. [28],
who demonstrated IS-dependent ROS production in a
monocytic cell line, and enhanced adhesion of these
cells to vascular endothelium in vitro [28]. They also
showed that IS reduction, by the administration of IS
absorbent – AST-120, significantly decreased ROS level in
monocytes of nephrectomized mice. Besides, Stinghen
et al. [42] demonstrated with in vitro and in vivo models
that exposure of the endothelium to uremic plasma results
in the increase of sVCAM-1 expression, which indicated a
link between vascular activation, systemic inflammation,and uremic toxicity. In addition, Tumur et al. [43] showed
that IS upregulated the expression of ICAM-1 by ROS-
induced activation of NF- κB in vascular ECs, and through
this mechanism may play an important role in the devel-
opment of CVD.
IS is one of the most investigated uremic toxins on
account of its negative impact on the cardiovascular
system. Clinical studies demonstrated that serum IS level
is a predictor of overall and cardiovascular mortality
[22, 23, 44]. On the other hand, Lin et al. proved that
elevated levels of PCS and IS are associated with increased
mortality in patients with CKD, while PCS, but not IS, is
associated with an increased risk of cardiovascular events
[45]. Although we could not establish the direct correl-
ation between plasma levels of IS and CVD prevalence,
we found an association between CVD and some
Table 5 The Spearman’s correlation between analyzed
hemostatic parameters and the markers of monocyte activation
(neopterin), oxidative stress (Cu/Zn SOD), inflammation (hs-CRP),









Coagulation TF 0.338 0.283 0.073 - 0.392
0.015 0.044 NS 0.004
F1 + 2 0.019 0.287 0.102 - 0.140
NS 0.041 NS NS
TFPI 0.179 0.325 0.325 - 0.402
NS 0.020 0.020 0.003
Fibrinolysis PAP 0.046 0.006 0.304 −0.027
NS NS 0.030 NS
uPA 0.179 0.287 0.247 - 0.329
NS 0.040 NS 0.018
suPAR 0.314 0.427 0.562 - 0.529
0.024 0.002 <0.0001 <0.0001
tPA −0.181 - 0.183 0.114 0.121
NS NS NS NS
PAI-1 −0.297 0.004 0.096 0.281
0.034 NS NS 0.046
Endothelial
function
vWF 0.076 0.165 0.330 - 0.172
NS NS 0.018 NS
TM 0.393 0.451 0.300 - 0.707
0.004 0.0008 0.033 <0.0001
sICAM-1 0.158 0.367 0.496 - 0.232
NS 0.008 0.0002 NS
sVCAM-1 0.527 0.448 0.467 - 0.569
<0.0001 0.0007 0.0006 <0.0001
Results are shown as Spearman’s rank correlation coefficients (R) and its
statistical significance (P values)
Abbreviations: TF tissue factor, F1 + 2 prothrombin fragments 1 + 2, TFPI tissue
factor pathway inhibitor, PAP plasmin-α2-antiplasmin, uPA urinary plasminogen
activator, suPAR soluble urokinase-type plasminogen activator receptor, tPA
tissue plasminogen activator, PAI-1 plasminogen activator inhibitor-1, vWF von
Willebrand Factor, TM thrombomodulin, sICAM-1 soluble intercellular adhesion
molecule-1, sVCAM-1 soluble vascular cell adhesion molecule-1, Cu/Zn SOD
Cu/Zn superoxide dismutase 1, hs-CRP high sensitivity C-reactive protein, eGFR
estimated glomerular filtration rate, NS non-significant
Appendix
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These factors were not only associated with CVD preva-
lence, but also the strong interrelationships existed be-
tween them (Table 4). This fact indicates that multiple
dysfunctions of the vascular cells were present among pa-
tients with CKD [46]. vWF is released into circulation by
activated ECs and mediates platelet adhesion to injured
endothelium – the first step in thrombus formation [47].
It is established that vWF has independent prognostic
value for all-cause mortality and CV events in peritoneal
dialyzed and hemodialyzed patients [48]. In accordance
with these data, our previous study [30] demonstrated that
vWF was independently associated with an early indicator
of systemic atherosclerosis – intima-media thickness in
CKD patients. An elevated suPAR level is thought to re-
flect activation of the inflammatory and immune systems,
and it predicts cancer, CVD, diabetes and mortality in the
general population [49]. The impact of suPAR on the car-
diovascular system in CKD is relatively unknown. Previ-
ously, we showed that uPA/suPAR system was associated
with hyperfibrinolysis, oxidative status and CVD preva-
lence in pre-dialysis and hemodialysis CKD patients
[29, 50]. The study of Meijers et al. [31] confirmed
that the higher suPAR level was directly associated with
both overall mortality and cardiovascular events in the
uremic population. sICAM-1 and sVCAM-1 trigger
leukocyte adhesion and migration into the subendothelial
space, initiating the formation of atherosclerotic lesions
[39]. Data of Stenvinkel et al. [51] suggest that sICAM-1 is
an independent predictor of mortality in pre-dialysis pa-
tients, who are malnourished, inflamed, and have signs of
CVD.
Although it is well established that both oxidative
stress, as well as monocyte activation, were associated
with CVD development in uremia [52], we showed for
the first time in clinical conditions that IS can be a fac-
tor linking these abnormalities with the prevalence of
CVD by a common mechanism associated with the dis-
orders of hemostatic system.
This study is limited due to its cross-sectional design
that makes us unable to establish precise mechanisms
underlying observed associations in view of various fac-
tors related to processes discussed in this work and
characteristic for CKD. Due to relatively small numbers
of patients, our results require further prospective co-
hort studies. Furthermore, our study did not focus on
the effect of the neutralization of IS toxicity mechanisms
by counteragents.
Conclusions
In conclusion, this study demonstrated for the first time
the involvement of IS in the disturbances of the
hemostatic system by the mechanism associated with oxi-
dative stress and monocytes activation, which can resultin the development of CVD in CKD patients on conserva-
tive treatment. Previously, we observed the impact of
kynurenines, the other components of tryptophan metab-
olism pathway, on disturbances of hemostasis and CVD
prevalence in CKD patients [24, 29, 31]. In this context,
the current study extends the knowledge concerning the
impact of tryptophan metabolites on a risk of cardiovascu-
lar complications in uremia. The clinical relevance of this
work may reside on the novel characterization of CKD pa-
tients’ populations at increased risk of cardiovascular
events, which are dependent from hemostatic disorders.
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